Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in non-ambulatory Duchenne muscular dystrophy
NCT04371666Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Aug 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Pamrevlumab with Placebo (2 arms). Primary endpoint: Total Score of Performance of Upper Limb (PUL) 2.0 Version at 52 weeks. Started Aug 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04371666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371666.